Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRN033
MIFTS: 37

Cranial Nerve Malignant Neoplasm

Categories: Cancer diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Cranial Nerve Malignant Neoplasm

About this section

MalaCards integrated aliases for Cranial Nerve Malignant Neoplasm:

Name: Cranial Nerve Malignant Neoplasm 12 15 17
Cranial Nerve Neoplasms 45 74
Malignant Neoplasm of Cranial Nerves 12
Malignant Tumor of the Cranial Nerve 12
Malignant Neoplasm of Cranial Nerve 12
Malignant Tumor of Cranial Nerve 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2815
ICD9CM 36 192.0
MeSH 45 D003390
NCIt 51 C3571
SNOMED-CT 69 93767009
ICD10 34 C72.50
Sources

Summaries for Cranial Nerve Malignant Neoplasm

About this section
MalaCards based summary : Cranial Nerve Malignant Neoplasm, also known as cranial nerve neoplasms, is related to cranial nerve neoplasm and malignant oculomotor nerve tumor. An important gene associated with Cranial Nerve Malignant Neoplasm is ENO2 (Enolase 2), and among its related pathways/superpathways is Neuroscience. The drugs Anti-Infective Agents and Gentamicins have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and spinal cord, and related phenotypes are nervous system and taste/olfaction

Sources

Related Diseases for Cranial Nerve Malignant Neoplasm

About this section

Diseases related to Cranial Nerve Malignant Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Related Disease Score Top Affiliating Genes
1 cranial nerve neoplasm 12.4
2 malignant oculomotor nerve tumor 11.3
3 alveolar soft part sarcoma 10.4 ENO2 SYP
4 chondrosarcoma, extraskeletal myxoid 10.4 ENO2 SYP
5 central nervous system benign neoplasm 10.4 ENO2 SYP
6 mixed cell type cancer 10.4 ENO2 SYP
7 sweat gland cancer 10.4 ENO2 SYP
8 optic nerve neoplasm 10.4 ENO2 SYP
9 central nervous system cancer 10.4 ENO2 SYP
10 medullomyoblastoma 10.4 ENO2 SYP
11 adult medulloblastoma 10.4 ENO2 SYP
12 optic nerve glioma 10.4 ENO2 SYP
13 pineal parenchymal tumor of intermediate differentiation 10.4 ENO2 SYP
14 hemangioblastoma 10.4 ENO2 SYP
15 cerebral primitive neuroectodermal tumor 10.4 ENO2 SYP
16 ependymoma 10.4 ENO2 SYP
17 tracheal cancer 10.4 AVP ENO2
18 ganglioneuroblastoma 10.4 ENO2 SYP
19 carotid body cancer 10.4 ENO2 SYP
20 malignant sertoli cell tumor 10.4 ENO2 SYP
21 sinonasal undifferentiated carcinoma 10.4 ENO2 SYP
22 pancreatic somatostatinoma 10.3 ENO2 SYP
23 papillary tumor of the pineal region 10.3 ENO2 SYP
24 sensory organ benign neoplasm 10.3 ENO2 SYP
25 middle ear adenoma 10.3 ENO2 SYP
26 central nervous system primitive neuroectodermal neoplasm 10.3 ENO2 SYP
27 cerebellum cancer 10.3 ENO2 SYP
28 clear cell ependymoma 10.3 ENO2 SYP
29 diffuse pulmonary fibrosis 10.3 CHGA ENO2
30 cerebral neuroblastoma 10.3 ENO2 SYP
31 extraosseous chondrosarcoma 10.3 ENO2 SYP
32 subependymal glioma 10.3 ENO2 SYP
33 astroblastoma 10.3 ENO2 SYP
34 tubular adenocarcinoma 10.3 CHGA SYP
35 cerebral ventricle cancer 10.3 ENO2 SYP
36 gastric tubular adenocarcinoma 10.3 CHGA SYP
37 pineal gland cancer 10.3 ENO2 SYP
38 melanotic neuroectodermal tumor 10.3 ENO2 SYP
39 mixed type thymoma 10.3 AVP SYP
40 benign ependymoma 10.3 ENO2 SYP
41 cystadenoma 10.3 CHGA SYP
42 ileum cancer 10.3 ENO2 NCAM1
43 intracranial primitive neuroectodermal tumor 10.3 CHGA ENO2
44 autonomic nervous system neoplasm 10.3 ENO2 NCAM1
45 rhabdoid cancer 10.3 ENO2 SYP
46 cloacogenic carcinoma 10.3 ENO2 POMC
47 desmoplastic small round cell tumor 10.3 ENO2 SYP
48 ureter small cell carcinoma 10.3 CHGA SYP
49 adrenal insufficiency, congenital, with 46,xy sex reversal, partial or complete 10.3 POMC SYP
50 adrenal cortical adenoma 10.3 POMC SYP

Graphical network of the top 20 diseases related to Cranial Nerve Malignant Neoplasm:



Diseases related to Cranial Nerve Malignant Neoplasm
Sources

Symptoms & Phenotypes for Cranial Nerve Malignant Neoplasm

About this section

MGI Mouse Phenotypes related to Cranial Nerve Malignant Neoplasm:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.56 AVP CHGA CNGA2 ENO2 NCAM1 OMP
2 taste/olfaction MP:0005394 8.8 CNGA2 ENO2 OMP
Sources

Drugs & Therapeutics for Cranial Nerve Malignant Neoplasm

About this section

Drugs for Cranial Nerve Malignant Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
2 Gentamicins Phase 4,Not Applicable
3 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
4
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 85622-93-1 5394
5
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
6 Alkylating Agents Phase 3,Phase 1,Phase 2,Early Phase 1
7 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2,Early Phase 1
8
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 5284616 6436030
9
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
10
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 70789204 6442177
11
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
12
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
13
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
14
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
15
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
16
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
17
Mebendazole Approved, Vet_approved Phase 1, Phase 2 31431-39-7 4030
18
Piperazine Approved, Vet_approved Phase 1, Phase 2 110-85-0 4837
19
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
20
Sodium Citrate Approved, Investigational Phase 1, Phase 2 68-04-2
21
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
22
Histamine Approved, Investigational Phase 2 51-45-6 774
23
Betahistine Approved, Investigational Phase 2 5638-76-6 2366
24
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
25
Citric Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
26
Lactitol Investigational Phase 2 585-88-6, 585-86-4 493591
27
Lapatinib Approved March 2007, Investigational Phase 2,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
28
tipifarnib Investigational Phase 2 192185-72-1 159324
29 Angiogenesis Modulating Agents Phase 2,Phase 1
30 Angiogenesis Inhibitors Phase 2,Phase 1
31 Endostatins Phase 2 71581480
32 Immunosuppressive Agents Phase 2,Phase 1,Early Phase 1
33 Immunologic Factors Phase 2,Phase 1,Early Phase 1
34 Antibiotics, Antitubercular Phase 2,Phase 1,Early Phase 1
35 Antifungal Agents Phase 2,Phase 1,Early Phase 1
36 Antibodies, Monoclonal Phase 2,Phase 1
37 Antineoplastic Agents, Immunological Phase 2,Phase 1
38 Antibodies Phase 2,Phase 1
39 Immunoglobulins Phase 2,Phase 1
40 Protein Kinase Inhibitors Phase 2,Phase 1,Early Phase 1
41 topoisomerase I inhibitors Phase 2,Phase 1
42 Topoisomerase Inhibitors Phase 2,Phase 1
43 Analgesics Phase 2
44 Anti-Inflammatory Agents, Non-Steroidal Phase 2
45 Analgesics, Non-Narcotic Phase 2
46 Anti-Inflammatory Agents Phase 2,Phase 1
47 Antipyretics Phase 2
48 Fibrinolytic Agents Phase 2
49 Cyclooxygenase Inhibitors Phase 2
50 Platelet Aggregation Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
3 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
4 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
5 Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Withdrawn NCT01260103 Phase 3 Temozolomide;ANP Therapy
6 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Unknown status NCT02934256 Phase 2 Icotinib
7 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
8 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
9 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
10 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
11 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
12 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
13 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
14 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
15 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
16 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma Completed NCT00003477 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
17 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
18 RGD PET/MRI in Sporadic Vestibular Schwannoma Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
19 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
20 Study of Aspirin in Patients With Vestibular Schwannoma Recruiting NCT03079999 Phase 2 Aspirin;Placebo
21 Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma Recruiting NCT02839720 Phase 2 Selumetinib
22 Multisession Radiosurgery for Optic Nerve Sheath Meningiomas Recruiting NCT02594709 Phase 2
23 Phase II Pegylated Interferon Recruiting NCT02343224 Phase 2 Pegylated interferon alpha-2b
24 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
25 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
26 Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting NCT01089101 Phase 1, Phase 2 Selumetinib
27 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
28 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT02129647 Phase 2 Axitinib
29 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
30 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma Active, not recruiting NCT01553149 Phase 2 Lenalidomide
31 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
32 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
33 AM-125 in the Treatment of Acute Peripheral Vertigo Following Vestibular Schwannoma Resection Not yet recruiting NCT03908567 Phase 2 Intranasal Drug;Oral Tablet
34 Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Not yet recruiting NCT03326388 Phase 1, Phase 2 Selumetinib
35 Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas Terminated NCT01338857 Phase 2 Sorafenib (Nexavar)
36 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
37 PTC299 for Treatment of Neurofibromatosis Type 2 Terminated NCT00911248 Phase 2 PTC299
38 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
39 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
40 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
41 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
42 Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Completed NCT00929903 Phase 1 pazopanib hydrochloride
43 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
44 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
45 Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Completed NCT00101270 Phase 1 irinotecan hydrochloride;oxaliplatin
46 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
47 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
48 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
49 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
50 Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas Completed NCT00012181 Phase 1 alvocidib

Search NIH Clinical Center for Cranial Nerve Malignant Neoplasm

Cochrane evidence based reviews: cranial nerve neoplasms

Sources

Genetic Tests for Cranial Nerve Malignant Neoplasm

About this section
Sources

Anatomical Context for Cranial Nerve Malignant Neoplasm

About this section

MalaCards organs/tissues related to Cranial Nerve Malignant Neoplasm:

42
Brain, Lung, Spinal Cord, Pituitary, Pineal, Ovary, Thyroid
Sources

Publications for Cranial Nerve Malignant Neoplasm

About this section

Articles related to Cranial Nerve Malignant Neoplasm:

# Title Authors Year
1
Predicting Readmission and Reoperation for Benign Cranial Nerve Neoplasms: A Nationwide Analysis. ( 30261394 )
2019
2
Morbid obesity increases risk of morbidity and reoperation in resection of benign cranial nerve neoplasms. ( 27434528 )
2016
3
Is Patient Age Associated with Perioperative Outcomes After Surgical Resection of Benign Cranial Nerve Neoplasms? ( 26855306 )
2016
Sources

Variations for Cranial Nerve Malignant Neoplasm

About this section
Sources

Expression for Cranial Nerve Malignant Neoplasm

About this section
Search GEO for disease gene expression data for Cranial Nerve Malignant Neoplasm.
Sources

Pathways for Cranial Nerve Malignant Neoplasm

About this section

Pathways related to Cranial Nerve Malignant Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.56 AVP ENO2 NCAM1 POMC SYP
Sources

GO Terms for Cranial Nerve Malignant Neoplasm

About this section

Cellular components related to Cranial Nerve Malignant Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 8.8 AVP CHGA POMC

Biological processes related to Cranial Nerve Malignant Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 generation of precursor metabolites and energy GO:0006091 8.62 AVP POMC
Sources

Sources for Cranial Nerve Malignant Neoplasm

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....